{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:51:06Z","timestamp":1761511866221},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2003,9,16]],"date-time":"2003-09-16T00:00:00Z","timestamp":1063670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,9,16]],"date-time":"2003-09-16T00:00:00Z","timestamp":1063670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2003,10,1]]},"DOI":"10.1038\/sj.bmt.1704209","type":"journal-article","created":{"date-parts":[[2003,9,16]],"date-time":"2003-09-16T15:06:18Z","timestamp":1063724778000},"page":"647-651","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results"],"prefix":"10.1038","volume":"32","author":[{"given":"J H","family":"Dalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Theoret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Duval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Larocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M F","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Champagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,9,16]]},"reference":[{"key":"BF1704209_CR1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/bbmt.2002.v8.pm12374453","volume":"8","author":"HF Fernandez","year":"2002","unstructured":"Fernandez HF et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486\u2013492.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704209_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","volume":"8","author":"JA Russell","year":"2002","unstructured":"Russell JA et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468\u2013476.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704209_CR3","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GW et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347\u20131353.","journal-title":"N Engl J Med"},{"key":"BF1704209_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.bmt.1701334","volume":"22","author":"AR Hartman","year":"1998","unstructured":"Hartman AR, Williams S, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan\/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439\u2013443.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/sj.bmt.1703207","volume":"28","author":"N Bleyzac","year":"2001","unstructured":"Bleyzac N et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28: 743\u2013751.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR6","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","volume":"80","author":"AM Yeager","year":"1992","unstructured":"Yeager AM et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425\u20132428.","journal-title":"Blood"},{"key":"BF1704209_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","volume":"26","author":"HT Tran","year":"2000","unstructured":"Tran HT et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463\u2013470.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/sj.bmt.1703229","volume":"28","author":"M Sandstrom","year":"2001","unstructured":"Sandstrom M et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001; 28: 657\u2013664.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR9","first-page":"2363","volume":"14","author":"G Vassal","year":"1994","unstructured":"Vassal G . Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res 1994; 14: 2363\u20132370.","journal-title":"Anticancer Res"},{"key":"BF1704209_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","volume":"25","author":"AM Bolinger","year":"2000","unstructured":"Bolinger AM et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925\u2013930.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/sj.bmt.1702700","volume":"26","author":"LL Dupuis","year":"2000","unstructured":"Dupuis LL, Najdova M, Saunders EF . Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2000; 26: 1143\u20131147.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bmt.1702590","volume":"26","author":"KS Baker","year":"2000","unstructured":"Baker KS et al. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 607\u2013614.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145\u2013154.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704209_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/sj.bmt.1702823","volume":"27","author":"Z Hassan","year":"2001","unstructured":"Hassan Z et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001; 27: 479\u2013485.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","volume":"6","author":"BS Andersson","year":"2000","unstructured":"Andersson BS et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548\u2013554.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704209_CR16","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.leu.2401921","volume":"14","author":"E Olavarria","year":"2000","unstructured":"Olavarria E et al. A phase I\/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000; 14: 1954\u20131959.","journal-title":"Leukemia"},{"key":"BF1704209_CR17","unstructured":"Wall D et al. Phase II trial of intravenous busulfan (Busulfex) with cyclophosphamide in pediatric allogeneic hematopoietic cell transplantation (HSC): pharmacokinetics, toxicity and efficacy (A Pediatric Blood and Marrow Transplant Consortium study). in: 42nd Annual Meeting of the American Society of Hematology Vol 97 edn. Hematology, A.S.o. (Blood, San Francisco, CA 2000)."},{"key":"BF1704209_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1046\/j.1365-2125.2002.01555.x","volume":"53","author":"S Cremers","year":"2002","unstructured":"Cremers S et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386\u2013389.","journal-title":"Br J Clin Pharmacol"},{"key":"BF1704209_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BF1704209_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/00007890-198506000-00005","volume":"39","author":"GB McDonald","year":"1985","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED . The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603\u2013608.","journal-title":"Transplantation"},{"key":"BF1704209_CR21","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/clinchem\/44.12.2506","volume":"44","author":"WK Lai","year":"1998","unstructured":"Lai WK et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem 1998; 44: 2506\u20132510.","journal-title":"Clin Chem"},{"key":"BF1704209_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0378-4347(98)00019-X","volume":"709","author":"MH Quernin","year":"1998","unstructured":"Quernin MH et al. Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl 1998; 709: 47\u201356.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BF1704209_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meir P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BF1704209_CR24","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225\u2013230.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704209_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/BF00257448","volume":"24","author":"G Vassal","year":"1989","unstructured":"Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J . Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386\u2013390.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1704209_CR26","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V82.3.1030.1030","volume":"82","author":"G Vassal","year":"1993","unstructured":"Vassal G et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030\u20131034.","journal-title":"Blood"},{"key":"BF1704209_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477\u2013485.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704209_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00686213","volume":"33","author":"M Hassan","year":"1993","unstructured":"Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M . Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181\u2013186.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704209","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:13:49Z","timestamp":1648077229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,16]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,10,1]]}},"alternative-id":["BF1704209"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704209","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,16]]},"assertion":[{"value":"18 December 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}